<PAGE>

================================================================================

                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                ______________

                                     1999
                                  FORM 10 - Q

                                For the Fiscal
                                SECOND QUARTER
                              Ended July 3, 1999

               Quarterly Report Pursuant To Section 13 or 15(d)
                    of the Securities Exchange Act of 1934

                              MOORE MEDICAL CORP.
            (Exact name of registrant as specified in its charter)
--------------------------------------------------------------------------------

Delaware                                                1-8903
(State of incorporation)                                (Commission File Number)

P.O. Box 1500, New Britain, CT 06050                    22-1897821
(Address of principal executive offices)                (I.R.S. Employer
                                                        Identification Number)

860-826-3600
(Registrant's telephone number)

          Securities registered pursuant to Section 12(b) of the Act:


Common Stock ($.01 Par Value)                            American Stock Exchange
Rights to Purchase Series I Junior Preferred Stock       American Stock Exchange
(Title of Each Class)                (Name of each exchange on which registered)
--------------------------------------------------------------------------------

     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding twelve months, and (2) has been subject to such filing
requirements for the past 90 days. Yes   X     No _____
                                       -----

                                   2,939,176

       Number of shares of Common Stock outstanding as of July 29, 1999

   Total number of pages in the numbered original (including exhibits) is 21


                          This is page 1 of 21 pages.
================================================================================
<PAGE>

                              MOORE MEDICAL CORP.


                                     Index

<TABLE>
<CAPTION>
                                                                                                 Page No.
                                                                                                 --------
<S>                                                                                              <C>
Part I.   Financial Information

          Item 1.   Financial Statements

                    Balance Sheets at the end of the second quarter of
                         1999 and at the end of the year 1998..................................        3

                    Statements of Operations for the second quarters
                         of 1999 and 1998......................................................        4

                    Statements of Operations for the first two quarters
                         of 1999 and 1998......................................................        5

                    Statements of Cash Flows for the first two quarters
                         of 1999 and 1998......................................................        6

                    Notes to Financial Statements..............................................        7

          Item 2.   Management's Discussion and Analysis of Results
                         of Operations and Financial Condition.................................     8-12


Part II.  Other Information

          Item 4.   Submission of Matters to a Vote of Security Holders .......................       12

          Item 6.   Exhibits and Reports on Form 8-K...........................................    12-21

          Signatures...........................................................................       13
</TABLE>

                                       2
<PAGE>

MOORE MEDICAL CORP.

<TABLE>
<CAPTION>
Balance Sheets at end of
---------------------------------------------------------------------------------------------------------------------
Amounts in thousands                                                        Second Quarter 1999            Year 1998
                                                                                (Unaudited)
---------------------------------------------------------------------------------------------------------------------
<S>                                                                         <C>                            <C>
ASSETS

Current Assets
       Cash                                                                     $      148                 $   3,520
       Accounts receivable, less allowances
           of $373 and $372............................................             11,330                     9,385
       Inventories.....................................................             14,259                    13,684
       Prepaid expenses and other current assets.......................              2,420                     1,992
       Deferred income taxes...........................................              2,500                     2,500
                                                                                ----------                 ---------
                Total Current Assets...................................             30,657                    31,081
                                                                                ----------                 ---------

Noncurrent Assets
       Equipment and leasehold improvements, net.......................              9,672                     7,038
       Other assets....................................................                263                       362
                                                                                ----------                 ---------
                Total Noncurrent Assets................................              9,935                     7,400
                                                                                ----------                 ---------
                                                                                $   40,592                 $  38,481
                                                                                ==========                 =========

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
       Accounts payable................................................         $    7,599                 $   5,421
       Accrued expenses................................................              6,150                     7,139
                                                                                ----------                 ---------
                Total Current Liabilities..............................             13,749                    12,560
                                                                                ----------                 ---------

Deferred Income Taxes..................................................                368                       368

Shareholders' Equity
       Preferred stock - no shares outstanding.........................                 --                        --
       Common stock - $.01 par value;
           5,000 shares authorized;
           3,246 shares issued.........................................                 33                        33
       Capital in excess of par value..................................             21,672                    21,667
       Retained earnings...............................................              7,502                     6,597
                                                                                ----------                 ---------
                                                                                    29,207                    28,297
       Less treasury shares, at cost, 307 and 308
           shares......................................................             (2,732)                   (2,744)
                                                                                ----------                ----------
                Total Shareholders' Equity.............................             26,475                    25,553
                                                                                ----------                ----------
                                                                                $   40,592                $   38,481
                                                                                ==========                ==========
---------------------------------------------------------------------------------------------------------------------
</TABLE>

The accompanying notes are an integral part of the financial statements.

                                       3
<PAGE>

MOORE MEDICAL CORP.

<TABLE>
<CAPTION>
Statements of Operations for the
--------------------------------------------------------------------------------------------------------------------
Amounts in thousands, except per share data                                              Second Quarter
                                                                           -----------------------------------------
                                                                                 1999                      1998
                                                                                          (Unaudited)
--------------------------------------------------------------------------------------------------------------------
<S>                                                                        <C>                         <C>
       Net sales........................................................     $ 29,367                   $ 30,042

       Cost of products sold............................................       20,152                     20,685
                                                                             --------                   --------

       Gross profit.....................................................        9,215                      9,357

       Selling, general & administrative expenses.......................        8,551                      8,250
                                                                             --------                   --------

       Operating income.................................................          664                      1,107

       Interest income, net.............................................            7                         18
                                                                             --------                   --------

       Income before income taxes.......................................          671                      1,125

       Income tax provision.............................................          243                        416
                                                                             --------                   --------

       Net income.......................................................     $    428                   $    709
                                                                             ========                   ========

       Basic and diluted net income per share...........................     $    .15                   $    .24
                                                                             ========                   ========
--------------------------------------------------------------------------------------------------------------------
</TABLE>

The accompanying notes are an integral part of the financial statements.

                                       4
<PAGE>

MOORE MEDICAL CORP.


<TABLE>
<CAPTION>
Statements of Operations for the
--------------------------------------------------------------------------------------------------------------------------
Amounts in thousands, except per share data                                           First Two Quarters
                                                                             --------------------------------------
                                                                              1999                      1998
                                                                                        (Unaudited)
--------------------------------------------------------------------------------------------------------------------------
<S>                                                                          <C>                       <C>
       Net sales........................................................     $ 58,422                  $ 60,981

       Cost of products sold............................................       39,698                    42,286
                                                                             --------                  --------

       Gross profit.....................................................       18,724                    18,695

       Selling, general & administrative expenses.......................       17,354                    16,951
                                                                             --------                  --------

       Operating income.................................................        1,370                     1,744

       Interest income, net.............................................           52                        24
                                                                             --------                  --------

       Income before income taxes.......................................        1,422                     1,768

       Income tax provision.............................................          517                       654
                                                                             --------                  --------

       Net income.......................................................     $    905                  $  1,114
                                                                             ========                  ========

       Basic and diluted net income per share...........................     $    .31                  $    .38
                                                                             ========                  ========
--------------------------------------------------------------------------------------------------------------------------
</TABLE>

The accompanying notes are an integral part of the financial statements.

                                       5
<PAGE>

MOORE MEDICAL CORP.

<TABLE>
<CAPTION>
Statements of Cash Flows for the
-----------------------------------------------------------------------------------------------------------------------
Amounts in thousands                                                                  First Two Quarters
                                                                             --------------------------------------
                                                                                1999                      1998
                                                                                        (Unaudited)
-----------------------------------------------------------------------------------------------------------------------
<S>                                                                          <C>                      <C>
Cash Flows From Operating Activities
       Net income............................................................ $   905                 $   1,114
       Adjustments to reconcile net income to net cash
           flows provided by operating activities:

           Depreciation and amortization.....................................     754                       613

           Changes in operating assets and liabilities
                Accounts receivable .........................................  (1,945)                    4,187
                Inventories..................................................    (575)                   (1,772)
                Other current assets.........................................    (428)                      372
                Accounts payable.............................................   2,178                    (2,702)
                Other current liabilities....................................    (886)                    1,559
                                                                              -------                 ---------
           Net cash flows provided by
                 operating activities........................................       3                     3,371
                                                                              -------                 ---------

Cash Flows From Investing Activities
       Equipment and leasehold improvements..................................  (3,388)                   (1,539)
                                                                              -------                 ---------

           Net cash flows used in investing activities.......................  (3,388)                   (1,539)
                                                                              -------                 ---------

Cash Flows From Financing Activities
       Revolving credit financing decrease, net..............................       -                    (1,512)

       Other, net............................................................      13                        64
                                                                              -------                 ---------
           Net cash flows provided by (used in)
            financing activities.............................................      13                    (1,448)
                                                                              -------                 ---------

(Decrease) increase in cash..................................................  (3,372)                      384
Cash at beginning of period..................................................   3,520                        54
                                                                              -------                 ---------

Cash At End Of Period........................................................ $   148                 $     438
                                                                              =======                 =========
-----------------------------------------------------------------------------------------------------------------------
</TABLE>

The accompanying notes are an integral part of the financial statements.

                                       6
<PAGE>

MOORE MEDICAL CORP.


NOTES TO FINANCIAL STATEMENTS

Note 1 -  Basis of Presentation of Financial Statements

          The accompanying financial statements should be read in conjunction
          with the Notes to Financial Statements and Management's Discussion and
          Analysis of Results of Operations and Financial Condition included in
          the Company's 1998 Annual Report filed on Form 10-K and in this Form
          10-Q Report.

          In the opinion of management, all adjustments necessary for a fair
          presentation of the results for the interim periods have been made.
          The results of operations for the second quarter and first two
          quarters are not necessarily indicative of the results to be expected
          for the full year. The fiscal quarters ended July 3, 1999 and July 4,
          1998.

Note 2 -  Contingencies

          Beginning in 1991, the Company entered into various supply contracts
          with the U.S. Department of Veterans Affairs and the Defense
          Department. In April 1997, the Company completed a review of its
          compliance with various pricing provisions of these contracts and,
          with the assistance of special legal counsel, concluded that
          adjustments may be due to the federal agencies for potential
          unasserted claims against the Company relating to pricing deficiencies
          under product supply contracts subject to General Services
          Administration and Department of Defense regulations. In the fourth
          quarter of 1996 the Company established a $3.8 million reserve for
          estimated pricing deficiency liabilities and associated legal costs.
          As of the end of 1998 and second quarter end of 1999, the reserve
          balance was $3.2 million. The final amount of the pricing deficiency
          adjustment is subject to the outcome of contract settlement
          discussions between the Company and the governmental agencies or to an
          adjudicated disposition. In management's opinion, the ultimate
          resolution of this matter will not have a material adverse effect on
          the Company's financial position. Although management believes that
          the reserve is sufficient, it is possible the final resolution could
          exceed such reserve and could have a material impact on the statement
          of operations and cash flow in such period.

          In 1997, the Company established a $4.5 million restructuring reserve
          relating to its exit from the wholesale drug distribution business. At
          the end of 1998, and the second quarter end of 1999, approximately
          $1.0 million and $0.8 million, respectively, remained.

                                       7
<PAGE>

MOORE MEDICAL CORP.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS
     AND FINANCIAL CONDITION


OVERVIEW
--------

The following table sets forth items included in the Statements of Operations as
a percentage of sales for the second quarters and first two quarters of 1999 and
1998, respectively. The table also shows, for each line item, the percentage
change in the 1999 periods from the comparable 1998 periods.

<TABLE>
<CAPTION>
                                                     Second Quarter                           First Two Quarters
                                         ---------------------------------------    ---------------------------------------
                                                % of Sales                %               % of Sales                 %
                                         -------------------------    ----------    ------------------------     ----------
                                            1999          1998          Change        1999          1998           Change
                                         -----------    ----------    ----------    ----------    ----------     ----------
<S>                                      <C>            <C>           <C>           <C>           <C>            <C>
Net sales............................       100.0%         100.0%           (2)%        100.0%        100.0%           (4)%
Cost of products sold................        68.6           68.9            (3)          68.0          69.3            (6)
                                           ------          -----                       ------        ------
Gross profit.........................        31.4           31.1            (2)          32.0          30.7             -
Selling, general & admin. exp........        29.1           27.4             4           29.7          27.8             2
                                           ------          -----                       ------        ------
Operating income.....................         2.3            3.7           (40)           2.3           2.9           (21)
Interest income, net...............             -              -           (61)          (0.1)            -           117
                                           ------          -----                       ------        ------
Income before income taxes...........         2.3            3.7           (40)           2.4           2.9           (20)
Income tax provision.................          .8            1.3           (42)            .9           1.1           (21)
                                           ------          -----                       ------        ------
Net income...........................         1.5%           2.4%          (40)%          1.5%          1.8%          (19)%
                                           ======          =====         =====         ======        ======         =====
</TABLE>


RESULTS OF OPERATIONS
---------------------

Second Quarter
1999 Compared with 1998
-----------------------

Net sales of $29.4 million for the second quarter of 1999 decreased 2% from the
same quarter of 1998 due primarily to the significant allocation of the
Company's human and financial capital required to implement a new state-of-the-
art Enterprise Resource Planning (ERP) system. The system was implemented to
provide timely, consistent company wide management and customer information.

For the 1999 second quarter, gross profit dollars decreased 2% to $ 9.2 million.
The gross profit margin rate in the 1999 quarter increased to 31.4% of sales
from 31.1% in the same quarter a year earlier. The improvement in margin rate is
attributable to a favorable product mix in sales.

                                       8
<PAGE>

Selling, general and administrative expenses in the second quarter of 1999
increased 4% from the quarter a year ago. The increase is primarily attributable
to expenses related to the implementation of the Company's ERP system for
training and outside consulting services.

Net income for the 1999 second quarter decreased 40%. The decrease was due
primarily to lower sales volume and expenses related to the implementation of
the Company's ERP system.

First Two Quarters
1999 Compared with 1998
-----------------------

Net sales for the first half of 1999 decreased 4% to $58.4 million from $61.0
million in the comparable 1998 period due to three major events: 1) the
Company's transition out of the wholesale drug distribution business, 2) the
liquidation of inventory related to this business in 1998 and 3) the investment
in human and financial capital related to the Company's implementation of a new
Enterprise Resource Planning (ERP) system.

For the 1999 first half, gross profit dollars remained flat with 1998 at $18.7
million. The gross profit margin rate in the 1999 half increased to 32.0% of
sales from 30.7% in the same period a year earlier. The improvement in rates is
primarily due to a favorable product sales mix.

Selling, general and administrative expenses during the first half of 1999
increased 2% compared with the first half of 1998. The increase is primarily due
to expenses related to the implementation of the Company's ERP system for
training and outside consulting services.

Net income for the first half of 1999 decreased 19% as compared to the same 1998
period. The decrease was attributable to the expenses associated with the
implementation of the Company's new ERP system.

FINANCIAL CONDITION
-------------------

During the first half of 1999, the Company's operating activities were cash
neutral and investing activities used $3.4 million in funds. Operating
activities used $3.8 million in cash from a $1.9 million increase in accounts
receivable, a $0.6 million increase in inventories and $1.3 million net change
in other assets and liabilities. Operating activities generated $3.8 million in
cash from a $2.2 million increase in accounts payable, $0.7 million in
amortization and depreciation and $0.9 million in net income. Investing
activities used $3.4 million for capital expenditures.

The Company's bank financing agreement provides a $10 million revolving line of
credit through December, 1999. Interest on loans is charged at the prime rate
or, at the option of the Company, at the Eurodollar rate plus a rate in a range
of 1% to 2%

                                       9
<PAGE>

depending on the financial leverage of the Company. In addition, the Company
pays a 1/4% commitment fee on the unused line of credit.

Management believes that the funding needs of the Company for operating working
capital and capital expenditures will continue to be met through income from
operations and financing available under its line of credit.

YEAR 2000 ISSUES
----------------

Year 2000 issues are the result of computer programs that were written using two
digits rather than four to define the applicable year. If the Company's computer
programs with date sensitive functions are not year 2000 compliant, they may
recognize a date using "00" as the year 1900 rather than the year 2000. This
could result in a system failure or miscalculations causing disruptions of
operations, including, an inability to process transactions, send invoices or
engage in other normal business activities.

The Company has identified its Year 2000 risks in three categories: internal
business software, internal non-information technology software, and external
vendor compliance.

Internal Information Technology
-------------------------------

During 1998, as part of a modernization program intended to improve productivity
and increase profitability by upgrading data processing, integrating systems and
enhancing internal reporting, the Company purchased an integrated enterprise
system which includes software which the vendor has represented to be Year 2000
compliant. The total estimated hardware, software, installation and training
cost of the integrated enterprise system, of which Year 2000 compliance is a
by-product, is $6.7 million, of which $6.2 million has been incurred through the
second quarter, funded through operating cash flow. The Company substantially
completed the implementation of the system during the second quarter of 1999.
With this implementation, the Company believes its internal information
technology systems to be in substantial compliance. However, if experience
should demonstrate that the implementation is not substantially complete, Year
2000 issues could have a material adverse impact on the Company's operations.
Contingency plans are being developed for areas where management considers there
may be some risk to modify certain of the major existing internal information
technology systems to be Year 2000 compliant.

Internal Non-Information Technology
-----------------------------------

The Company has assessed the Year 2000 compliance of its internal
non-information software and of the technology embedded in such systems as
security, telecommunications and building systems by contacting the providers of
such systems. Written assurance of Year 2000 compliance has been received from
substantially all providers.

                                       10
<PAGE>

External Vendor Compliance
--------------------------

The Company has identified and contacted its major suppliers, service providers
and contractors ("vendors") to determine the extent of their Year 2000
compliance. The process is substantially complete. To the extent that responses
were unsatisfactory, the Company intends to consider changing the vendors to
those who have represented Year 2000 readiness, but cannot be assured that it
will be successful in finding alternative vendors. In the event that a major
vendor's written assurance of Year 2000 compliant becomes questionable and the
Company does not replace it with a new vendor, its business could be materially
adversely affected. The Company is formulating a contingency plan for major
vendors' Year 2000 non-compliance.

FORWARD-LOOKING INFORMATION
---------------------------

From time to time, the Company or its representatives may have made or may make
forward-looking statements, orally or in writing. Such forward-looking
statements may be included in, but, not limited to, press releases, oral
statements made by or with the approval of an authorized executive officer, or
in this report or other filings made by the Company with the Securities and
Exchange Commission. The words or phrases "trend," "expect," "grow," "will,"
"could," "likely result," "planned," "intends," "continued," "anticipated,"
"estimated," "projected" or similar expressions are intended to identify
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. The Company wishes to ensure that such statements
are accompanied by meaningful cautionary statements, so as to maximize to the
fullest extent possible the protections of the safe harbor established in the
said Act. Accordingly, such statements are qualified in their entirety by
reference to and are accompanied by the following discussion of certain
important factors that could cause actual results to differ materially from such
forward-looking statements.

Investors should also be aware of factors that could have an impact on the
Company's business or financial position or performance. These include possible:
pressures on revenues resulting, for example, from customer consolidations or
changes in customer buying patterns; intensified competition resulting, for
example, from distributor consolidations or pricing pressures from distributors
able to benefit from economies of scale or other operating efficiencies;
disruptions in services on which the Company is dependent, such as by truckers
in deliveries from its suppliers, by UPS or other common carriers in deliveries
to its customers, by its catalog printers or in telecommunication services, or
relating to its computer systems; unfavorable outcomes of litigation to which
the Company may become a party; and other factors detailed from time to time in
the Company's Securities and Exchange Commission filings or other readily
available or generally disseminated writings. The risks identified here are not
all inclusive. Reference is also made to other parts of this report that include
additional information concerning factors that could adversely impact the
Company's business or financial position or performance. Moreover, the Company
operates in a changing and very competitive business environment. New risks may
emerge from time to time, and

                                       11
<PAGE>

it is not possible for management to predict all risk factors, nor can it
necessarily identify or assess the impact of all such factors on the Company or
the extent to which any factor or combination of factors may cause actual
results to differ materially from those contained in any forward-looking
statements. Accordingly, forward-looking statements should not be relied upon as
a prediction of actual results.

PART II.  OTHER INFORMATION
          -----------------

Item 4.   Submission of Matters to a Vote of Security Holders
          ---------------------------------------------------

          (a)  The 1999 Annual Meeting of Shareholders of the Company was held
               May 12, 1999.

          (b)  At the Annual Meeting, the following persons were elected
               directors, with the following number of shares voted for and
               withheld:

                                               For               Withheld
                                          ---------------      -------------

               Steven Kotler                 2,259,359            11,606
               Robert H. Steele              2,259,359            11,606
               Peter C. Sutro                2,259,359            11,606
               Wilmer J. Thomas, Jr.         2,259,359            11,606
               Dan K. Wassong                2,259,359            11,606


Item 6.   Exhibits and Reports on Form 8-K
          --------------------------------

          (a)  Exhibits
               --------

               Fifth Amendment to Revolving Credit               Exhibit 10.18
               Agreement by the Company and BankBoston,
               N.A., dated April 30, 1999

               Financial Data Schedule                           Exhibit 27

          (b)  Reports on Form 8-K
               -------------------

               No report on Form 8-K was filed during the quarter.

                                       12
<PAGE>

                                  SIGNATURES
                                  ----------

     Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

MOORE MEDICAL CORP.
(REGISTRANT)


By: /s/ David V. Harper                      By: /s/ Susan G. D'Amato
    -------------------------                    -------------------------------
    David V. Harper, Executive                   Susan G. D'Amato, Vice
    Vice President - Finance and                 President and Controller
    Chief Financial Officer                      August 10, 1999
    August 10, 1999

                                       13